SCHEMBL30406544

SCHEMBL30406544

Cc1ccc(NCc2ccc(F)cc2)cc1NCCn1cncn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.40
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PTK2 Q05397 1/20 0.38
NAMPT P43490 1/20 0.38
KCNQ3 O43525 1/20 0.37
KCNQ2 O43526 1/20 0.37
KCNQ4 P56696 1/20 0.37
KCNQ5 Q9NR82 1/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C19 P33261 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CACNA1B Q00975 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608967 0.94 QPCT (0.39) CYP19A1LMNASMN1; SMN2PTK2KCNQ3
SCHEMBL23608966 0.80 CYP19A1 (0.40) CYP19A1LMNASMN1; SMN2PTK2NAMPT
SCHEMBL29973640 0.80 CYP19A1 (0.40) CYP19A1LMNASMN1; SMN2PTK2NAMPT
SCHEMBL23608953 0.77 CYP19A1 (0.38) CYP19A1LMNASMN1; SMN2PTK2NAMPT
SCHEMBL23608948 0.77 GPR55 (0.47) CYP19A1LMNASMN1; SMN2NAMPTCYP1A2
SCHEMBL30406696 0.75 NTRK1 (0.35) CYP19A1LMNASMN1; SMN2PTK2NAMPT
SCHEMBL23608983 0.75 CYP19A1 (0.43) CYP19A1LMNASMN1; SMN2NPC1RAB9A
SCHEMBL23608949 0.74 CYP19A1 (0.44) CYP19A1LMNANAMPTKDM4EALDH1A1
SCHEMBL30406745 0.74 CACNA1B (0.35) CYP19A1LMNAPTK2NAMPTCYP1A2
SCHEMBL23608959 0.73 SMN1; SMN2 (0.42) CYP19A1LMNASMN1; SMN2NAMPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117592-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230117592-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX5 CYP19A1 153/4885LMNA 1170/4885SMN1; SMN2 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.